CHAPTER 4.

Guideline for the Care of the Older Adult With Diabetes

Medha Munshi, MD; Elizabeth Blair, MSN, ANP-BC, CDE, CDTC; Om P. Ganda, MD, Chair, Clinical Oversight Committee; Robert A. Gabbay, MD, PhD, FACP; and the members of the Joslin Guidelines Committee

From the Adult Diabetes and Clinical Research sections, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts

This guideline was revised and approved May 17, 2017, and updated February 7, 2018.

Objective: The Joslin Guideline for the Care of the Older Adult with Diabetes is designed to assist primary care physicians, specialists, and other healthcare providers in addressing the unique challenges and issues of the older person with diabetes. The guideline should be used in conjunction with Joslin’s Clinical Guideline for Adults with Diabetes as well as Joslin’s Clinical Guideline for Pharmacological Management of Adults with Type 2 Diabetes (T2D).

The primary goal of diabetes management in older adults is to achieve balance between optimal glycemic control to prevent and/or slow the onset and progression of acute and chronic complications, while avoiding hypoglycemia and its consequences. Hypoglycemia can result in worse outcomes in older adults as it can lead to traumatic falls and worsening of chronic conditions such as cognitive dysfunction. Therefore, in many cases, aggressive treatment may not be appropriate if the older adult’s comfort, safety, and overall quality of life are thereby compromised, or if aggressive treatment may not improve outcomes. Recent consensus on the management of diabetes recommends individualization of treatment goals based on coexisting medical conditions, cognitive status, functionality, and available resources. The older adult’s view on illness, health, and aging should also be considered. Appropriate support systems for complex diabetes are not uniformly available nationwide. As a result, treatment decisions become more complex as the capacity to cope with self-care declines.

To assist with self-care, education strategies also require adaptation for aging. Learning new diabetes self-management skills may be difficult for older people, increasing the need for education to proceed in a simple, step-like manner. Cognitive dysfunction, depression, and functional disabilities (such as vision and hearing deficits and a decline in dexterity) are important issues to consider when assessing the older adult’s ability for self-care. Involvement of family members or friends may be required to assure appropriate self-care and adherence to treatment programs.

Portions of this guideline are based upon recommendations of the International Diabetes Federation’s Global Guideline for Managing Older People with Type 2 Diabetes and the American Diabetes Association/American Geriatrics Society Consensus Report on Diabetes in Older Adults.
### 4.1.0 GENERAL CONSIDERATIONS

- In determining treatment plans and goals, individualized patient assessment is required, being cognizant of the following:
  - Chronological age versus actual health status
  - Duration of disease and age of onset (for example, older-age onset of T2D is more prominent in non-Hispanic whites and is associated with a lower likelihood of insulin use than middle-age onset; retinopathy is more likely to occur in middle-age–onset diabetes rather than older-age–onset diabetes. There is no difference in coronary artery disease or neuropathy prevalence in middle vs older age onset)
  - Presence of complications and comorbidities
  - Life expectancy
  - Social support system
  - Financial status
  - Patient preferences
- Treatment programs should be simplified to decrease medication safety or efficacy
- Voices lack of trust in medications
- List names and doses of medications
- Inability to accurately follow-up with exercise recommendations
- Discrepancies between log book and meter download
- Reports of falls
- Severe uncontrolled sleep
- Severe uncontrolled pain
- Severe uncontrolled incontinence
- Severe uncontrolled constipation
- Severe uncontrolled fever
- Severe uncontrolled nausea/vomiting

**TABLE 1. Geriatric Syndrome: Screening and Modifications**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Clinical Presentation</th>
<th>Shorn Screening Test</th>
<th>Modification to Treatment Plans and Goals</th>
</tr>
</thead>
</table>
| Cognitive dysfunction              | • Decline in self-care and/or worsening of glycemic control without clear etiology  
• Appears stubborn or not able to follow instructions  
• Seems uninterested in helping him/herself  
• Makes errors, especially when problem-solving | • Clock drawing test  
• MiniCog test  
• Montreal Cognitive Assessment Test | • Avoid tight glucose control and complex diabetes medication programs  
• Educate caregivers and seek their support in managing the patient’s diabetes  
• Repeat important education topics at each visit, eg, how to recognize and treat hypoglycemia  
• Avoid diabetes medications that have a risk of hypoglycemia, as the hypoglycemia may go unnoticed and untreated  
• Recommend reminders, such as alarms, notes, and pill boxes, for taking medications or eating meals |
| Depression                         | • Seems uninterested in helping him/herself  
• Is less interested in activities  
• Seems overwhelmed with life events  
• Has a decline in self-care and/or worsening of glycemic control without clear etiology | • Patient Health Questionnaire (PHQ-2)  
• Geriatric Depression Scale | • Assess and treat depression |
| Physical disabilities              | • Vision impairment  
• Hearing loss  
• Gait abnormality  
• Dosing errors  
• Discrepancies between log book and meter download  
• Disinterest in conversation  
• Inactivity, lack of follow-up with exercise recommendations  
• Reports of falls | • Vision and hearing screening  
• Physical exam to evaluate for peripheral neuropathy  
• Ask about recent falls and fear of falls  
• Assess for risk factors for falls  
• Bone-density study to evaluate bone health and fracture risk | • Recommend use of assistive devices for vision and hearing impairment, such as hearing aids, talking glucose meters, glucose meters with large readouts, magnifiers  
• Recommend use of assistive devices such as cane or walker for balance and gait issues  
• Recommend safe-venue, supervised exercise program/physical therapy  
• Recommend an exercise program that is suitable for the patient’s current level of activity, eg, wheelchair exercises, exercise pedals, etc |
| Malnutrition/weight loss            | • Weight loss  
• Dental issues | • Nutrition assessment tools, eg, DETERMINE survey | • Avoid restrictive diets; encourage adequate calories, hydration, protein intake, nutrition supplements  
- Consider Meals on Wheels if unable to shop/cook for self  
- Consider communal meals at senior centers if socially isolated  
- Consider community food pantries if finances impede healthy food purchases  
• Encourage regular dental checkups |
| Polypharmacy/medication nonadherence | • Fluctuations in glucose, blood pressure, and/or cholesterol levels  
• Inability to accurately list names and doses of medications  
• Voices lack of trust in medication safety or efficacy  
• Appears overly medicated | • Carefully reconcile medication list at each visit  
• Assess for lack of resources | • Ask patient to carry current medication list with them  
• Ask patient what he/she actually takes on the list of medications they carry  
• When possible, discontinue medications that have no clear benefit  
• Look for medication adverse effect or drug–drug interaction as the possible cause of any new symptoms  
• If needed, review patient’s medication refill history with their pharmacy  
• Refer patient/family to financial resources to assist with obtaining needed medications |

the potential of medication errors and to avoid overwhelming the patient and their caregivers.

- Treatment goals should be reassessed at frequent intervals as health status can change quickly in older adults.

### 4.2.0 GERIATRIC SYNDROME

The table in this guideline (Table 1) lists a group of conditions collectively called geriatric syndrome, which occurs more frequently in older adults with diabetes. These conditions can interfere with a patient’s ability to perform self-care activities and make healthcare more challenging for the older adult and for their caregivers. The table below includes the condition, possible clinical presentations, commonly used short clinical screening tests, and suggested modifications to treatment plans and goals to compensate for the condition.

### 4.3.0 DIAGNOSIS

See Joslin’s Clinical Guideline for Adults with Diabetes (Chapter 1) for more details. CDC data indicate that about half of older adults have prediabetes. It is recommended that all adults ≥45 years of age be screened for diabetes every 1 to 3 years using a glycated hemoglobin (A1C), fasting glucose, or oral glucose tolerance test. This recommendation should be modified for those with shorter life expectancies and those with multiple comorbidities.

### 4.4.0 TREATMENT GOALS

See Joslin’s Clinical Guideline for Adults with Diabetes for more details. Treatment goals are modified for health status, based on recommendations from the American Diabetes Association.

| TABLE 2. Treatment Goals for the Older Adult |
|-------------------------------|------------------------------|------------------|------------------|-------------------|------------------|
| **Patient Characteristics/Health Status** | **Rationale** | **A1C** | **Fasting or Postprandial Glucose (mg/dL)** | **Bedtime Glucose (mg/dL)** | **Blood Pressure (mmHg)** |
| Healthy | Longer life expectancy | <7.5% [1C] | 80-130 | 90-150 | <140/90 [2B] |
| Complex/intermediate | Intermediate life expectancy | <8% [2C] | 90-150 | 100-180 | <150/90 [2C] |
| Very complex/poor health | Limited life expectancy | <8.5% [2C] | 100-180 | 110-200 | <150/90 [2C] |

Source: American Diabetes Association; *Coexisting chronic illnesses: conditions serious enough to require medication or lifestyle management. They may include arthritis, cancer, congestive heart failure, depression, chronic obstructive pulmonary disease, falls, and chronic renal failure.

*ADL: measures functioning in traveling, shopping, housework, managing finances, using the telephone, and taking medications.

A1C indicates glycated hemoglobin.

### 4.5.0 EDUCATION

Education strategies require adaptation for aging. Simplify and focus programs:

- Use focused educational material that is easy to follow and excludes extraneous information.
- Provide individual rather than group education if the patient has cognitive or physical deficits.
- Focus on 1 to 2 topics at a time. Repetition and re-education are needed for many older adults.
- Education sessions should be slow-paced, with instruction occurring in steps.
- Multiple sessions may need to be scheduled, to prevent “information overload.”
- Use memory aids (e.g., personalized handouts) to reinforce points made during face-to-face sessions.
- When possible, simplify the patient’s medication program especially for those who have multiple medical problems, cognitive dysfunction, or functional disability (e.g., changing insulin to 2 injections per day from 4 injections per day).
- When discussing medications, focus education on medication adherence by using charts, pill boxes, and other reminders.
- Caregivers should be instructed in how to track amounts of medication used.
- Educate the patient that uncommon symptoms such as health status can change quickly in older adults.
4.6.0 DEVICES
- Recommend equipment that is easy to hold, easy to read, and requires the least number of steps.
- Insulin pens, pens that contain noninsulin glucose-lowering medication, and prefilled syringes may be easier for older patients to use than manipulating a syringe and vial. Syringe magnifiers are available if vision is impaired.
- For some patients, inhaled insulin may be another option for prandial insulin.
- Choose blood glucose meters that have a large display, are easy to hold and use, and that minimize handling of strips and lancets. “Talking meters” are available for those with vision impairment.

4.7.0 MONITORING
- Emphasize the importance of regular self-monitoring of blood glucose (SMBG), especially before driving or using power tools.
- Checking glucose levels at different times of the day, on different days of the week, will allow the provider to assess glucose patterns throughout the day without having the patient check the glucose several times each day. For example, check the fasting and presupper glucose levels one day, and prelunch and bedtime levels another day.
- Some older adults may not be able to perform SMBG due to physical or cognitive impairment. To decrease the risk of hypoglycemia in these situations, glycemic goals may need to be adjusted and medication programs may need to be simplified. In T2D, if appropriate, use diabetes medications that have a low risk for hypoglycemia.
- Develop a plan to treat hypoglycemia. Encourage the patient to carry a source of glucose on their person and to have one at the bedside at all times.
- Develop a sick day plan.
- Encourage caregivers to accompany patients to education sessions and receive appropriate education in glucose monitoring and blood glucose interpretation.

4.8.0 DRIVING
- A referral for education and counseling should be advised if the patient’s ability to drive is in question. Organizations such as local elder services, the American Geriatric Society, and the various state motor vehicle registries may have additional information for patients as well as family members.
- Drive-wise programs, where available, can be useful to assess the patient’s ability to drive.

4.9.0 NUTRITION CHALLENGES (see Appendix for examples of nutrition prescriptions)
Although diabetes nutritional guidelines for the older adult are no different than for younger adults, unique challenges often exist due to:
- Lack of motivation
- Impaired food shopping or preparation capabilities
- Omission of meals due to cognitive dysfunction or depression
- Compromised dentition
- Altered taste perception
- Altered gastrointestinal function
- Weight loss and malnutrition
- Coexisting illnesses
- Limited finances

4.9.1 Nutritional recommendations:
Consider referral to a dietitian to work with the older adult patient and caregivers to:
- Assess nutritional needs
- Avoid making unnecessary dietary changes in life-long eating habits, remembering that to treat coexisting illnesses multiple changes may be required, such as reducing potassium, sodium, and dietary fats
- Minimize the complexity of meal planning and engage the spouse, or others living with the patient, in creating a home environment that supports positive lifestyle change
- Educate how consistency in carbohydrate intake and meal timing can help minimize fluctuations in blood glucose levels as well as help maintain or achieve a reasonable weight
- Consider giving prandial insulin after the meal rather than before, based on carbohydrate intake
- Assess the ability to buy and prepare healthy meals
- Help maximize a limited food budget
- Suggest community resources such as Meals on Wheels

4.9.2 Weight loss/potential malnutrition:
- Weight-loss diets commonly recommended to younger adults should be prescribed with great caution to the older adult, since undernutrition/malnutrition is often more of a problem than obesity in the older adult.
- Weight loss and the potential for malnutrition should be carefully monitored, especially after acute illness, hospitalization, and social stress.
  - Use serial weight measurements to monitor changes.
- To avoid weight loss, it may be necessary to let patients...
eat what they enjoy and adjust diabetes medications accordingly.

4.9.3 Chronic care settings:
- In chronic care settings, there is no need for a rigid and restrictive meal plan. A regular meal plan with consistent, moderate carbohydrate intake may be sufficient and may help avoid undernutrition.

4.10.0 PHYSICAL ACTIVITY
(see Appendix for examples of activity prescriptions)

4.10.1 Benefits of activity:
Physical activity should be stressed in all older adults as it is crucial in maintaining functionality, independence, and acceptable quality of life.
- Regular exercise program offers other benefits to older adults, such as:
  - Reduced glucose levels
  - Improved lipid profile
  - Improved blood pressure
  - Increased muscle tone and strength
  - Improved gait and balance
  - Overall physical conditioning
  - Decreased depression, and an overall sense of improved well-being.

4.10.2 Types of activity:
- Types of physical activities that may be appropriate for the older adult should take into account the current level of physical fitness/disability. It is important to develop an activity program to increase mobility, endurance, and strength, and to increase the duration of the activity gradually. Common activities to achieve these goals include:
  - Aerobic activities
  - Walking
  - Swimming or water aerobics
  - Stationary bicycle riding
  - Resistance training
  - Armchair exercises
  - Weight lifting
  - Balance exercise
  - Tai chi
  - Yoga
  - Flexibility exercises
  - Other physical activities:
    - Gardening
    - Household chores

4.10.3 Challenges to consider:
- Challenges to maintaining a regular physical activity program include:
  - Fluctuations in health
  - Comorbidities, such as cardiovascular disease, osteoarthritis, and osteoporosis
  - Risk and fear of falls
  - Finding a safe environment for exercise
  - Issues with transportation
  - Hypoglycemia
    - The risk of hypoglycemia is increased among those using insulin and other diabetes medications that can cause hypoglycemia. More frequent SMBG may reduce this risk.
- An exercise physiologist or a physical or occupational therapist can provide a supervised environment to help a patient perform exercises safely.

4.11.0 MEDICATIONS: GENERAL CONSIDERATIONS
General principles to consider when prescribing medications to an older adult include:
- “Start low and go slow” when dosing and titrating medications
- Agents with low risk of hypoglycemia are preferred in this age group
- Deintensification (or simplification) of complex regimens is recommended to reduce the risk of hypoglycemia

4.11.1 Overtreatment of diabetes is common in older adults and should be avoided.
- Consider drug–drug interactions carefully, as most older adults are on multiple medications as well as supplements
- Evaluate renal function using the estimated glomerular filtration rate (eGFR) rather than serum creatinine because low muscle mass in the older population may result in a “normal” creatinine level despite significant renal dysfunction
- Monitor liver and kidney function with periodic tests
- Assess financial resources when using newer, generally more expensive agents

4.11.2 Oral glucose-lowering medications: (Table 3)
Please also refer to Joslin’s Clinical Guideline for Pharmacological Management of Adults With Type 2 Diabetes (Chapter 1) for more detailed information on diabetes medications.

4.11.3 Injectable noninsulin antidiabetic medications (Table 4)

4.11.4 Insulin products (Table 5)

4.12.0 HYPERTENSION: GENERAL CONSIDERATIONS
The goals of therapy for hypertension in the older adult are the same as those for younger adults with diabetes. The target blood pressure should be less than 140/90 mmHg as tolerated. Isolated systolic hypertension is much more common in the older adult.
Systolic blood pressure <150 is acceptable in patients with multiple comorbidities or limited life expectancy. Care should be taken to treat with antihypertensive agents to bring systolic blood pressure to goal, if feasible. Blood pressure should be lowered gradually in order to reduce the risk of hypotensive symptoms. Older adults are prone to “white coat” hypertension. If suspected, patients should be asked to measure blood pressure at home and keep a log for periodic evaluation.

### 4.12.1 Antihypertensive drugs (Table 6)

### 4.13.0 LIPIDS (for more detail please see Joslin’s Clinical Guideline for Adults with Diabetes Chapter 1)

**TABLE 3. Oral Antidiabetic Medications**

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Mechanism of Action</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Caveats in the Older Population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biguanides</strong></td>
<td>Decrease hepatic glucose production, increase GLP-1 secretion</td>
<td>Low risk for hypoglycemia</td>
<td>Contraindicated in advanced liver disease, alcohol excess, compensated congestive heart failure, acute intercurrent illness, dehydration</td>
<td>Use as initial therapy unless contraindicated</td>
</tr>
<tr>
<td>• liquid metformin*</td>
<td></td>
<td>Low cost</td>
<td>AEs include gas, diarrhea, B12 deficiency, lactic acidosis</td>
<td>Initiate at low dose, increase dose slowly, and take with food to decrease gas, diarrhea</td>
</tr>
<tr>
<td>• (Romet)</td>
<td></td>
<td>Well understood AEs</td>
<td></td>
<td>Extended release formulation may decrease GI symptoms</td>
</tr>
<tr>
<td>• metformin (Glucophage)</td>
<td></td>
<td></td>
<td></td>
<td>May cause weight loss</td>
</tr>
<tr>
<td>• metformin extended</td>
<td></td>
<td></td>
<td></td>
<td>May cause GI symptoms initially or symptoms may develop after prolonged use</td>
</tr>
<tr>
<td>• release (Glucophage XR, Fortamet, Glumetza)</td>
<td></td>
<td></td>
<td></td>
<td>Measure liver functions, serum creatinine, and eGFR initially, then periodically and with any increase in dose</td>
</tr>
<tr>
<td>*Liquid formulation for patients unable to swallow large tablets</td>
<td></td>
<td></td>
<td></td>
<td>Avoid initiating and stop use if eGFR &lt;45</td>
</tr>
<tr>
<td><strong>Insulin secretagogues</strong></td>
<td></td>
<td></td>
<td></td>
<td>Consider use of short-acting sulfonylurea in the setting of renal disease to reduce the risk for hypoglycemia</td>
</tr>
<tr>
<td><strong>Sulfonylureas</strong></td>
<td>Stimulate beta-cell insulin secretion</td>
<td>Many sulfonylureas are available at lower cost</td>
<td>Contraindicated in severe liver or renal disease</td>
<td>Repaglinide or nateglinide may be useful for those with postprandial hyperglycemia or hypoglycemia on sulfonylurea</td>
</tr>
<tr>
<td>• glibenclamide (Amaryl)</td>
<td></td>
<td>Shorter-acting agents like glipizide, or the nonsulfonylurea insulin secretagogues repaglinide and nateglinide, may lower the risk of nocturnal hypoglycemia. In patients with erratic oral intake, these drugs may lower the risk of daytime hypoglycemia</td>
<td>Risk of hypoglycemia, especially with longer-acting sulfonylureas such as chlorpropamide (first-generation sulfonylurea) and glyburide</td>
<td>Watch for increased risk of hypoglycemia in those with memory issues, or that may accompany acute illness, hospitalization, weight loss, lack of appetite, and skipped meals</td>
</tr>
<tr>
<td>• glipizide (Glucotrol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• glipizide extended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• release (Glucotrol XR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• glyburide (Micronase, Diabeta)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• micronized glyburide (Glynase)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Meglitinides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• repaglinide (Prandil)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D-phenylalanine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• derivatives (Prandil)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• nateglinide (Starlix)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TZDs</strong></td>
<td>Improve glucose transport; decrease hepatic glucose production</td>
<td>TZDs can be well tolerated in healthy older adults as they do not cause hypoglycemia</td>
<td>Fluid retention and CHF are common comorbidities in the elderly, preventing the use of TZDs</td>
<td>AEs of fluid retention can be limiting factors in using this class of medications</td>
</tr>
<tr>
<td>• pioglitazone (Actos)</td>
<td></td>
<td>Can be used in renal impairment but may increase fluid retention</td>
<td>Should be avoided in patients with Class III and Class IV CHF</td>
<td>Concerns re: bladder cancer are fewer in the elderly with shorter life expectancy</td>
</tr>
<tr>
<td>• rosiglitazone (Avandia)</td>
<td></td>
<td></td>
<td>See footnotes 1-3 for CV and other risks</td>
<td>See footnotes 1-3 for CV and other risks</td>
</tr>
</tbody>
</table>

**GENERAL CONSIDERATIONS**

- All individuals with preexisting cardiovascular disease (CVD): Based on a large body of clinical-trial evidence, all individuals with preexisting CVD should be treated with high-intensity statin therapy designed to lower low-density lipoprotein cholesterol (LDL-C) by ≥50% from baseline, regardless of baseline cholesterol. The adherence to statin therapy should be monitored at 4 to 12 weeks after initiation, and every 3 to 12 months thereafter, as indicated.
- If age >75 years, or if adverse events occur while on a high-intensity statin dose, treat with moderate-intensity statin therapy, designed to lower LDL-C between
### TABLE 3 (cont.). Oral Antidiabetic Medications

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Mechanism of Action</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Caveats in the Older Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>Delay absorption and breakdown of carbohydrates</td>
<td>Use if postprandial hyperglycemia predominates</td>
<td>Contraindicated in chronic intestinal disorders</td>
<td>Modest glucose-lowering effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low risk of hypoglycemia if used as monotherapy</td>
<td>May cause gas, diarrhea</td>
<td>Ideally, use pure glucose to treat hypoglycemia when used in combination therapy, because the drugs decrease absorption of other forms of carbohydrate</td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>In a glucose-dependent manner, these medications slow the inactivation of incretin hormones, resulting in increased insulin secretion and decreased glucagon levels</td>
<td>Helpful in controlling postprandial glucose elevations</td>
<td>Lower risk of hypoglycemia</td>
<td>Low risk of hypoglycemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AEs include occasional diarrhea and stomach discomfort</td>
<td>Safety of use in the setting of prior pancreatitis is unknown. Stop medication if pancreatitis is suspected when a DPP-4 inhibitor is in use</td>
<td>Assess kidney function prior to initiating and periodically thereafter</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High cost</td>
<td>Lower glucose-lowering efficacy may result in the need for a multidrug program</td>
<td>Reduce dose in renal disease with some members of the class</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased risk for CHF with saxagliptin</td>
<td>Postmarketing reports of hepatic failure with alogliptin</td>
<td>Good drug for frail elderly with newly diagnosed diabetes</td>
</tr>
<tr>
<td>SGLT2 inhibitors</td>
<td>Block the reabsorption of glucose by the proximal tubule of the kidney, thereby increasing excretion of glucose in the urine</td>
<td>Low risk of hypoglycemia</td>
<td>Do not use dapagliflozin in setting of bladder cancer; use with caution with a history of bladder cancer</td>
<td>Adjust dose in mild kidney disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Do not use in moderate-to-severe renal disease as it may worsen renal function</td>
<td>May reduce blood pressure</td>
<td>To decrease the risk of hypotension and dehydration, consider adjustment of antihypertensive medication, especially diuretics, when starting this medication class</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased risk for genital mycotic infections and for urinary tract infection</td>
<td>May result in dehydration, weight loss, hyperkalemia, increased low-density lipoprotein cholesterol</td>
<td>Do not use dapagliflozin in setting of bladder cancer; use with caution with a history of bladder cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May result in dehydrated, weight loss, hyperkalemia, increased low-density lipoprotein cholesterol</td>
<td>High cost</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Little data available for safety in the older population</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Many of the oral diabetes medications are available in fixed combinations. Please see Joslin’s Clinical Guideline for Pharmacological Management of Adults with Type 2 Diabetes. Fixed combinations have the advantage of 1 versus 2 co-payments. Adherence may improve as there are fewer tablets to administer and to remember. The disadvantage to fixed combinations is decreased flexibility in dosing. Colesevelam, a bile acid sequestrant, and quick-release bromocriptine are approved by the FDA for the treatment of diabetes, but there is very limited use in the older population.

**Footnotes**

1. There is an increased risk for edema when insulin and a T2D are used together. Rosiglitazone should not be used in combination with insulin.
2. FDA requirements for liver function tests with T2Ds: If initial alanine aminotransferase (ALT) is $>$2.5 times normal, do not start this medication. Once T2D is started, monitor ALT periodically thereafter according to clinical judgment. If ALT is $>$2.5 times normal during treatment, check weekly. If rise persists or becomes $>$3 times normal, discontinue T2D.
3. Some T2Ds cause or exacerbate congestive heart failure in some patients. After initiation of T2Ds and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain; dyspnea; and/or edema). If these signs and symptoms develop, the heart failure should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of the T2D must be considered. T2Ds are not recommended in patients with symptomatic heart failure or in patients with established New York Heart Association Class III or IV heart failure.
4. On September 23, 2010, the FDA announced regulatory actions with respect to products containing rosiglitazone: Avandia (rosiglitazone maleate) tablets, Avandamet (rosiglitazone maleate and metformin hydrochloride) tablets, and Avandaryl (rosiglitazone maleate and glimepiride) tablets. These FDA actions required GlaxoSmithKline to implement restrictions on the use of these products through a Risk Evaluation and Mitigation Strategy (REMS) program to assure their safe use and through additional labeling changes in response to the agency’s review of data that suggested an elevated risk of CV events. However, based on additional data review, the REMS program was removed as of May 2014. Rosiglitazone now has the same indications for prescribing as pioglitazone.
5. According to an FDA advisory issued on June 15, 2011, on potentially increased risk of bladder cancer with pioglitazone use: a) do not use pioglitazone in patients with active bladder cancer; b) use pioglitazone with caution in patients with a prior history of bladder cancer. The benefits of glycemic control versus unknown risks for cancer recurrence with pioglitazone should be considered in patients with a prior history of bladder cancer.

**Footnotes**

- AE indicates adverse effect; CHF, congestive heart failure; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; GLP-1, glucagon-like peptide-1; SGLT2, sodium glucose co-transporter-2; TZD, thiazolidinedione.
30% and 49% from baseline. If the baseline LDL-C is not known, the minimum target should be LDL-C <70 mg/dl, or non–HDL-C <100 mg/dl.

**For primary prevention in older people aged ≤75 years:** Statin therapy should be based on 10-year CVD risk as calculated by the revised risk calculator (my.americanheart.org/cvriskcalculator).

If the 10-year risk is <7.5%, a moderate-to-intensive statin therapy is indicated, designed to lower LDL-C by 30% to 50% from baseline. If the baseline LDL-C is not known, the minimum target should be LDL-C <70 mg/dl, or non–HDL-C <100 mg/dl.

If the 10-year risk is ≥7.5%, intensive statin therapy should be instituted, designed to lower LDL-C by ≥50% from baseline, regardless of baseline cholesterol. If the baseline LDL-C is not known, the minimum target should be LDL-C <70 mg/dl, or non–HDL-C <100 mg/dl.

**For primary prevention in older people aged >75 years:** Initiation of statin therapy is of uncertain value, and should be individualized, based on comorbidities, life expectancy, safety considerations, and priorities of care. Consider stopping statin therapy if life expectancy is less than 1 year.

### 4.13.1 Lipid-lowering medications (Table 7)

#### 4.13.1.1 Injectable Noninsulin Antidiabetic Medications (TABLE 4)

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Mechanism of Action</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Caveats in the Older Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incretin mimetics</td>
<td>In a glucose-dependent manner, increase insulin secretion, decrease glucagon secretion, slow gastric emptying, and increase satiety</td>
<td>Use may be associated with weight loss, which is helpful in the overweight/obese person</td>
<td>Mediations must be injected</td>
<td>Low risk of hypoglycemia, and formulation that can be used once weekly, makes this an attractive agent to use in elderly</td>
</tr>
<tr>
<td>• exenatide (Byetta)</td>
<td></td>
<td></td>
<td>Dosing frequency is dependent on the medication and can range from twice a day to once weekly</td>
<td>Consider the person’s cognitive abilities, dexterity, and visual acuity before considering use of any injectable medication</td>
</tr>
<tr>
<td>• liraglutide (Victoza)</td>
<td></td>
<td></td>
<td>Adverse effects include nausea, diarrhea, and increased satiety, which can affect nutritional status in the older adult</td>
<td>To decrease risk of hypoglycemia if using with a sulfonylurea or basal insulin, consider initially decreasing sulfonylurea or insulin dose</td>
</tr>
<tr>
<td>• extended release exenatide (Bydureon)</td>
<td></td>
<td></td>
<td>Low risk of hypoglycemia</td>
<td></td>
</tr>
<tr>
<td>• dulaglutide (Trulicity)</td>
<td></td>
<td></td>
<td>Formulation that can be used once weekly, makes this an attractive agent to use in elderly</td>
<td></td>
</tr>
<tr>
<td>• semaglutide (Ozempic)</td>
<td></td>
<td></td>
<td>Limited data on safety in the older population</td>
<td></td>
</tr>
</tbody>
</table>

### 4.14.0 FOOT CARE

- Recommendations for foot examinations and treatment in older adults with diabetes are the same as those for younger individuals. Older adults may require additional education and devices such as mirrors to examine their feet due to decreased mobility and dexterity. See Joslin’s Clinical Guideline for Adults With Diabetes for more detail.
- Older adults should be encouraged to see a podiatrist regularly. Medicare provides coverage for podiatrist visits every 9 weeks, along with special footwear for patients with diabetes-related qualifying foot problems.

### 4.15.0 EYE CARE

Recommendations for eye examinations and treatment in older adults with diabetes are the same as those recommended in Joslin’s Clinical Guideline for Adults with Diabetes.

- Providers should also consider eye conditions commonly seen in older adults, including glaucoma, macular degeneration, and cataracts, which may be present without evidence of diabetic eye disease or coincident with diabetic eye disease.
  - Nondiabetic ocular conditions such as cataracts may complicate evaluation and treatment of diabetic retinopathy
  - Interventions for nondiabetic ocular conditions may be risk factors for progression of diabetic retinopathy
  - Interventions for diabetic eye disease may pose risk factors for progression of nondiabetic eye conditions such as cataracts and glaucoma
- Although tighter glycemic control has been shown to lower the risk of eye complications, the overall risk of hypoglycemia and increased mortality risk with tight control in the older population should be considered when setting the glycemic goals.
### 4.11.4. Insulin Products (TABLE 5)

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Mechanism of Action</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Caveats in the Older Population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Injectable U-100 insulins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rapid-acting:</strong></td>
<td>• Insulin aspart analog (Novolog)</td>
<td>Allow glucose to enter cells for an energy source; decrease hepatic glucose production</td>
<td>Improved glucose control in type 2 diabetes when used in combination with other anti diabetic medications, or when other programs do not give adequate control. Insulin can be used as monotherapy</td>
<td>Older adult patients taking insulin often face difficulties with self-administration because of reduced dexterity, impaired vision, and cognitive deficits. Risk of hypoglycemia</td>
</tr>
<tr>
<td></td>
<td>• Insulin glulisine analog (Apidra)</td>
<td></td>
<td></td>
<td>Consider the person's type of diabetes, cognitive abilities, dexterity, and visual acuity before considering the use of insulin. Long-acting insulin can be used safely with other noninsulin diabetes medications to control postprandial glycemia. When deciding on the timing and dose of basal insulin, consider the individual's glucose pattern. In general, older adults have a higher contribution of postprandial hyperglycemia compared with fasting hyperglycemia. Thus, starting basal insulin in the morning in this population may decrease the risk of nocturnal hypoglycemia and improve postprandial glucose control. It is often beneficial to use simpler insulin regimens with fewer daily injections, such as premixed insulin preparations and easier injection systems (e.g., insulin pens with easy-to-set dosages). If syringe and vial are to be used, a careful assessment of the individual's ability to draw up and give an injection needs to be made prior to devising the insulin and self-monitoring program. The risk for hypoglycemia when using premixed insulins is lessened when meal times are more fixed. There is a potential increased risk for nocturnal hypoglycemia when taking a premixed insulin at the evening meal. Other self-management skills, such as treating hypoglycemia and eating on a regular schedule, will need to be assessed prior to determining the person’s insulin program and reassessed periodically thereafter.</td>
</tr>
<tr>
<td></td>
<td>• Insulin lispro analog (Humalog)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short-acting:</strong></td>
<td>• Human Regular</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Humulin R</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Novolin R</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intermediate-acting:</strong></td>
<td>• Human NPH insulin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Humulin N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Novolin N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Long-acting:</strong></td>
<td>• Insulin detemir (Levemir)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Insulin glargine (Lantus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Insulin degludec (Tresiba)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Premixed insulins:</strong></td>
<td>• 70% NPH; 30% Regular (Humulin 70/30)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 70% NPH; 30% Regular (Novolin 70/30)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 50% lispro protamine suspension, 50% lispro (Humalog Mix 50/50)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 75% lispro protamine suspension, 25% lispro (Humalog Mix 75/25)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 70% aspart protamine suspension, 30% aspart (Novolog Mix 70/30)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injectable U-300 Insulin</strong></td>
<td></td>
<td></td>
<td></td>
<td>Limited experience. May be used in patients with large insulin requirement (greater than 200 units daily).</td>
</tr>
<tr>
<td><strong>Injectable U-500 Insulin</strong></td>
<td></td>
<td></td>
<td></td>
<td>May be used in patients with large insulin requirement (greater than 200 units daily).</td>
</tr>
<tr>
<td><strong>Inhaled insulin</strong></td>
<td>Afrezza inhalation insulin</td>
<td>May be used instead of prandial insulin.</td>
<td>Older adult patients taking insulin often face difficulties with self-administration because of reduced dexterity, impaired vision, and cognitive deficits. Risk of hypoglycemia Need to ensure normal pulmonary function periodically</td>
<td>Limited experience.</td>
</tr>
</tbody>
</table>

NPH indicates neutral protamine Hagedorn; T1D, type 1 diabetes.
### 4.12.1. Antihypertensive Drugs (TABLE 6)

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Mechanism of Action</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Caveats in the Older Population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACEI/ARB</strong></td>
<td>Inhibition of the renin-angiotensin system</td>
<td>Evidence for cardiovascular benefits</td>
<td>Dry cough with ACEI</td>
<td>Before initiating therapy, check baseline renal function and serum potassium; recheck within 1-2 weeks of initiation of therapy, with each medication dose increase, and at least yearly thereafter</td>
</tr>
<tr>
<td>Examples:</td>
<td></td>
<td>Evidence for renal protection</td>
<td>Hyperkalemia</td>
<td></td>
</tr>
<tr>
<td>ACEIs:</td>
<td></td>
<td></td>
<td>Drop in eGFR</td>
<td></td>
</tr>
<tr>
<td>lisinopril, ramipril, benazepril, trandolapril</td>
<td></td>
<td>(contraindicated in renal vascular disease)</td>
<td>Angioneurotic edema with ACEI (rare)</td>
<td></td>
</tr>
<tr>
<td>ARBs:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>losartan, valsartan irbesartan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diuretics</strong></td>
<td>Sodium excretion; limit volume expansion</td>
<td>May be effective as monotherapy, also additive blood-pressure-lowering effect with other agents</td>
<td>Hypokalemia</td>
<td>Before initiating therapy, check baseline electrolytes; recheck electrolytes within 1-2 weeks of initiation of therapy, with each medication dose increase, and at least yearly thereafter</td>
</tr>
<tr>
<td>Include hydrochlorothiazide, chlorothalidone, furosemide, torsemide, bumetanide, indapamide</td>
<td></td>
<td>Volume depletion</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Calcium channel blockers</strong></td>
<td>Direct vascular effects by inhibition of calcium channels</td>
<td>Potent antihypertensive effect</td>
<td>Fluid retention with certain agents in class (amlodipine, diltiazem)</td>
<td>Some evidence suggests that treatment with calcium channel blockers, diuretics, and ACE inhibitors are more effective than beta blockers in this population</td>
</tr>
<tr>
<td>Include diltiazem, verapamil, amlodipine</td>
<td>May have greater effect in stroke prevention</td>
<td>Bradycardia with certain agents in class (diltiazem, verapamil)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Beta blockers</strong></td>
<td>Reduce cardiac output</td>
<td>Evidence for cardiovascular benefits after acute coronary events</td>
<td>Bradycardia, fatigue</td>
<td>May be less effective in older adults and African Americans</td>
</tr>
<tr>
<td>Include metoprolol, atenolol, propranolol, carvedilol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mineralocorticoid receptor antagonists</strong></td>
<td>Inhibit mineralocorticoid receptor</td>
<td>Additive effects as antihypertensives or in heart failure</td>
<td>Hyperkalemia</td>
<td>Before initiating therapy, check baseline renal function and serum potassium; recheck within 1-2 weeks of initiation of therapy, with each medication dose increase, and at least yearly thereafter</td>
</tr>
<tr>
<td>Include spironolactone, eplerenone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Combination therapy</strong></td>
<td></td>
<td></td>
<td>Most patients require more than 1 antihypertensive medication to reach goal</td>
<td></td>
</tr>
</tbody>
</table>

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.
### 4.13.1. Lipid-Lowering Medications (TABLE 7)

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Mechanism of Action</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Caveats</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HMG CoA-R reductase inhibitors (statins)</strong></td>
<td>Reduce cholesterol synthesis and promote cholesterol excretion by enhancing the activity of LDL receptors</td>
<td>Drug class of choice for lowering LDL-C on the basis of many clinical trials</td>
<td>3%-6% probability of liver toxicity; 10%-15% probability of myalgia or muscle weakness; rarely myositis or rhabdomyolysis</td>
<td>Check ALT within 4-12 weeks of initiation of the medication, with each dose increase, and with any signs or symptoms of liver dysfunction</td>
</tr>
<tr>
<td>• atorvastatin (Lipitor)</td>
<td></td>
<td></td>
<td>May precipitate new-onset diabetes, especially in those with prediabetes or metabolic syndrome</td>
<td>Routine CK measurements are not necessary unless symptoms warrant</td>
</tr>
<tr>
<td>• fluvastatin (Lescol)</td>
<td></td>
<td></td>
<td>Older adults on medications for hyperlipidemia should have periodic evaluation of liver enzymes</td>
<td></td>
</tr>
<tr>
<td>• lovastatin (Altoprev, Mevacor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• pitavastatin (Livalo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• pravastatin (Pravachol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• rosuvastatin (Crestor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• simvastatin (Zocor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ezetimibe</strong></td>
<td>Reduces cholesterol absorption</td>
<td>Well tolerated</td>
<td>Modest effect; lowers LDL-C by 15%-20% Rare AEs</td>
<td>May improve CVD event reduction when added to moderate-dose statin, if statin intensification not feasible</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Not preferred in monotherapy, but may be useful as adjunct to statin, if statin alone cannot be intensified</td>
</tr>
<tr>
<td><strong>Bile acid sequestrants</strong></td>
<td>Bind to bile acids and promote excretion of cholesterol in gut</td>
<td>Dose-dependent reduction in LDL-C, 15%-30% Can be combined with statins</td>
<td>Adherence issues due to GI AEs</td>
<td>Limited data on CVD event reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Not preferred in monotherapy unless other agents can’t be used</td>
</tr>
<tr>
<td><strong>Niacin</strong></td>
<td>Inhibits lipolysis, and has multiple lipid effects via diverse mechanisms</td>
<td>Dose-dependent lowering of LDL-C by 10%-20%; raises HDL-C by 15%-25%; lowers TG 15%-30% Additive efficacy with statins in achieving lipid goals</td>
<td>Adherence issues due to multiple AEs, including flushing, pruritus, liver toxicity, hyperuricemia, and raised glucose levels</td>
<td>Effects on CVD prevention unproven</td>
</tr>
<tr>
<td><strong>Fibrates</strong></td>
<td>Inhibit lipolysis and VLDL production; enhance triglyceride clearance</td>
<td>Drug of choice to lower TG; raises HDL-C; minimal effect on LDL-C</td>
<td>Myalgia in combination with other drugs, including statins Caution in presence of CKD; may promote gallstones</td>
<td>Limited data on CVD event reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Indicated in preventing pancreatitis, if TG &gt;500 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Additional studies on CVD events underway</td>
</tr>
<tr>
<td><strong>Omega-3 fatty acids</strong></td>
<td>Inhibit triglyceride synthesis in liver</td>
<td>Well tolerated 25%-30% reduction in TG levels; modest effects on HDL-C; may raise LDL-C</td>
<td>Adherence issues May prolong bleeding time</td>
<td>No data on CVD event reduction; studies ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Currently approved to lower TG if &gt;500 mg/dL; may reduce risk of pancreatitis</td>
</tr>
<tr>
<td><strong>PCSK 9 inhibitors</strong></td>
<td>Antibody to PCSK9 further reduces LDL-C in combination with statin or if statin intolerant</td>
<td></td>
<td>Expensive</td>
<td>Limited data in elderly</td>
</tr>
</tbody>
</table>

AE indicates adverse effect; ALT, alanine aminotransferase; CK, creatinine kinase; CVD, cardiovascular disease; GI, gastrointestinal; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; TG, triglycerides; VLDL, very low-density lipoprotein cholesterol.
REFERENCES


**Appendix**

### Examples of Exercise Prescriptions

<table>
<thead>
<tr>
<th>For inactive or frail patients</th>
<th>For active patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do the items checked below. If an item is not checked, ignore it.</td>
<td>Do the items checked below. If an item is not checked, ignore it.</td>
</tr>
<tr>
<td>• Walk 5 minutes inside the house or in the hallway, every day o Start with 1-3 times a day before meals o Increase a little each week to 10 minutes 3 times every day</td>
<td>• Aerobic activity: Do 1 of these at least 5 days each week. You can do the same one each time or pick a different one for variety. Start with short periods of time and increase to 30-60 minutes a day. o Walking (use pedometer to increase activity as tolerated) o Stationary bike o Swimming o Water aerobics</td>
</tr>
<tr>
<td>• Pedal with legs and arm o Start with what you can do and increase a little each week up to 15-20 minutes every day</td>
<td>• Resistive training: Do 1 of these at least 2 days each week. You can do the same one each time or pick a different one for variety. Start with no/low weights and increase weights and repetitions as tolerated, up to 8-10 reps for 2-3 cycles for each muscle group o Hand weights (or 8-ounce water bottle) o Resistance bands o Use machines at gym</td>
</tr>
<tr>
<td>• Stationary bike o Start with 5 minutes, 1-3 times a day o Increase a little each week up to 30 minutes every day</td>
<td>• Stretching: Do 1 of these daily. You can do the same one each time or pick a different one for variety. Again, start low and go slow. Avoid excessive stretching and injury. o Yoga o Stretching</td>
</tr>
</tbody>
</table>

### Examples of Nutrition Prescriptions

<table>
<thead>
<tr>
<th>To avoid low blood sugar</th>
<th>Nutrition prescriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not skip or delay meals</td>
<td>Do the items checked below. If an item is not checked, ignore it.</td>
</tr>
<tr>
<td>Have some carbohydrate/starch to eat at each meal</td>
<td>Do not skip or delay meals</td>
</tr>
<tr>
<td>Keep glucose tablets/gel or hard candy with you at all times</td>
<td>Have some carbohydrate/starch to eat at each meal</td>
</tr>
<tr>
<td>Check your blood sugar anytime you feel unwell, sick, or confused</td>
<td>Have at least 1500 mg of calcium and 800 units of vitamin D every day</td>
</tr>
<tr>
<td>Eat a snack before any significant activity</td>
<td>Eat a snack at bedtime</td>
</tr>
<tr>
<td></td>
<td>Eat a snack between meals</td>
</tr>
<tr>
<td></td>
<td>Eat a snack before any physical activity</td>
</tr>
</tbody>
</table>

### Basic Activities of Daily Living

- **Bathing**: includes grooming activities such as shaving, and brushing teeth and hair
- **Dressing**: choosing appropriate garments and being able to dress and undress, having no trouble with buttons, zippers or other fasteners
- **Eating**: being able to feed oneself
- **Transferring**: being able to walk, or, if not ambulatory, being able to transfer oneself from bed to wheelchair and back
- **Continence**: being able to control one’s bowels and bladder, or manage one’s incontinence independently
- **Toileting**: being able to use the toilet

### Instrumental Activities of Daily Living

- **Using the telephone**: being able to dial numbers, look up numbers, etc
- **Managing medications**: taking the appropriate medications and correct dosages on time
- **Preparing meals**: making appropriate food choices and preparing meals safely
- **Maintaining the home**: doing or arranging for housekeeping and laundry
- **Managing finances**: budgeting, paying mortgage/rent and bills on time, etc
- **Shopping**: being able to shop for groceries and other small necessities, and transport purchases from store to home
- **Using transportation**: being able to drive or use public transportation for appointments, shopping, etc

### Depression Screening

Over the past 2 weeks, how often have you been bothered by any of the following problems?

- Little or no interest or pleasure in doing things
  - 0: not at all
  - 1: several days
  - 2: more than half the days
  - 3: nearly every day

- Feeling down, depressed, or hopeless
  - 0: not at all
  - 1: several days
  - 2: more than half the days
  - 3: nearly every day

**Total score (Add a. and b.): ____________**

(If patient scores >0, administer full Geriatric Depression Scale)